Stratum Corneum Defensive Functions: An Integrated View  by Elias, Peter M.
See related Commentary on page ix
Stratum Corneum Defensive Functions: An Integrated View
Peter M. Eliasw
Dermatology Service, Veterans Affairs Medical Center and wDepartment of Dermatology, University of California, San Francisco, California, USA
Most epidermal functions can be considered as protective, or more speciﬁcally, as defensive in nature. Yet, the
term ‘‘barrier function’’ is often used synonymously with only one such defensive function, though arguably its
most important, i.e., permeability barrier homeostasis. Regardless of their relative importance, these protective
cutaneous functions largely reside in the stratum corneum (SC). In this review, I ﬁrst explore the ways in which the
multiple defensive functions of the SC are linked and interrelated, either by their shared localization or by common
biochemical processes; how they are co-regulated in response to speciﬁc stressors; and how alterations in one
defensive function impact other protective functions. Then, the structural and biochemical basis for these
defensive functions is reviewed, including metabolic responses and signaling mechanisms of barrier homeostasis.
Finally, the clinical consequences and therapeutic implications of this integrated perspective are provided.
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Defensive Functions of the Stratum
Corneum (SC)
Defensive functions of SC primarily localize to either the
cellular or extracellular compartment Virtually all epider-
mal functions (with the exception of vitamin D production)
can be considered protective, and most of these critical
protective functions further localize to the SC (Elias and
Feingold, 2003). The structural organization of the SC into a
two-compartment system largely dictates the localization of
specific defensive functions to either the corneocyte or ex-
tracellular matrix (Table I). Lamellar bodies (LB), which se-
crete a variety of proteins and lipids into the extracellular
spaces, further mandate that an array of functions reside in
the SC interstices (Fig 1). In addition to the provision of
lipids for the barrier, LB deliver: (1) lipid processing enzymes
that process lipid precursors into their respective products
(Freinkel and Traczyk, 1983; Grayson et al, 1985); (2) pro-
teases that orchestrate desquamation (e.g., serine proteas-
es (SP)) (Sondell et al, 1994; Braissant et al, 1996; Braissant
and Wahli, 1998); (3) anti-proteases, such as elafin and
cystatin M/E; (4) corneodesmosin (CDSN), a novel protein of
the outer epidermis that coats the external face of corn-
eodesmosomes (CD) (Haftek et al, 1996), rendering them
resistant to premature proteolysis (Lundstrom et al, 1994);
and (5) antimicrobial peptides, e.g., human b-defensin 2
(hBD2) (Oren et al, 2003).
How are protective functions linked? Although it is con-
venient to consider each defensive function as a discrete
process, many individual functions co-localize, and/or they are
linked biochemically or by common regulatory mechanisms.
Co-localization of permeability and antimicrobial barriers In
addition to presenting a daunting physical barrier to path-
ogenic microbes that attempt to penetrate from the envi-
ronment, the epidermis also generates a spectrum of
antimicrobial lipids, peptides, toll-like receptors, and che-
mokines that together comprise cutaneous innate immunity
(Gallo and Nizet, 2003; Ganz, 2003). The ability of the skin to
both restrict water loss from the body, and the ingress of
microbial pathogens through the SC, results from its or-
ganization into a two-component system of lipid-depleted
corneocytes embedded in a lipid-enriched, extracellular
matrix (Table I). It is the: (i) absolute quantities, (ii) hydro-
phobic character, (iii) lipid distribution, and (iv) supra-
molecular organization of its constituent lipids into a series
of lamellar bilayers (Elias and Menon, 1991) that together
account for the permeability barrier. Three of these SC
lipids exhibit robust antibacterial activity in vitro (i.e.,
Abbreviations: AD, atopic dermatitis; aSMase, acidic sphingomye-
linase; CD, corneodesmosome; CDSN, corneodesmosin; CE,
cornified envelope; CLE, corneocyte-bound lipid envelope; DSC,
desmocollin; DSG, desmoglein; EHK, epidermolytic hyperkerato-
sis; FFA, free fatty acids; FLIM, fluorescence life-time imaging; b-
GlcCer’ase, b-glucocerebrosidase; hBD, human beta-defensin; ;
IL-1, interleukin-1; LB, lamellar body; LI, lamellar ichthyosis; LXR,
liver X receptor; NHE, sodium-proton exchanger; NHR, nuclear
hormone receptors; o-OH-Cer, o-hydroxy ceramides; PL, phos-
pholipids; PPAR, peroxisome proliferator activator receptor; SC,
stratum corneum; SCCE, stratum corneum chymotryptic enzyme;
SCCP, stratum corneum cysteine protease; SCTE, stratum corn-
eum tryptic enzyme; SG, stratum granulosum; SP, serine proteas-
es; sPLA2, secretory phospholipase A2; SPT, serine palmitoyl
transferase; SREBP, sterol regulatory element binding proteins; TG,
transglutaminase; TNF, tumor necrosis factor; UCA, urocanic acid;
UV, ultraviolet light
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free fatty acids (FFA), glucosylceramides, and the Cer hy-
drolytic product, sphingosine (Miller et al, 1988; Bibel et al,
1992).
Mammalian epidermis also expresses several types of
antimicrobial peptides: the a-defensins, hNP1 and 2, the b-
defensins, hBD1–4, and a cathelicidin, hCAP (Gallo and Ni-
zet, 2003; Ganz, 2003), the S100 protein, psoriasin (Glaser
et al, 2005), and a novel antimicrobial RNase, RNase 7
(Harder and Schro¨der, 2002). Defensins comprise small,
cationic, and cysteine-enriched members of a highly con-
served gene family, consisting of a and b subtypes, which
differ slightly in their disulfide-bond pairing, genomic or-
ganization, and tissue distribution (Ganz, 2003). a-defensins
are present in neutrophils and the small intestine (Paneth
cells), but only at low levels in the skin. All four b-defensins
are expressed in keratinocytes, and exhibit potent antimi-
crobial activity against a variety of Gram-negative and
Gram-positive bacteria, yeast, and viruses. But the activity
of individual defensins against specific microbial targets
differs greatly, e.g., hBD3, but not hBD2, is active against
Staphylococcus aureus (Dunsche et al, 2002; Ganz, 2003).
hBD2 and 3 further localize to the outer epidermis and
both are activated by primary cytokines, such as interleukin
(IL-1)a and tumor necrosis factor (TNF)a (Huh et al, 2002;
Liu et al, 2002; Oren et al, 2003). The co-localization of the
permeability and antimicrobial barriers is demonstrated viv-
idly by the translocation of hBD2 from the endoplasmic re-
ticulum to epidermal LB following IL-a stimulation (Oren
et al, 2003), with subsequent sequestration of hBD2 within
SC membrane domains (Huh et al, 2002). Through its lo-
calization in the SC interstices, hBD2 is positioned to inter-
cept pathogenic microbes as they attempt to penetrate
between corneocytes.
The human epidermis also expresses the cathelicidin,
hCAP-18 (Zaiou and Gallo, 2002; Gallo and Nizet, 2003).
Cathelicidins are a class of small, cationic peptides with a
highly conserved, NH-terminal cathelin segment that pos-
sesses cysteine protease inhibitory activity, and a C-termi-
nal segment (LL-37) (Zaiou and Gallo, 2002). The latter
possesses a broad spectrum of antimicrobial activity in-
cluding against viruses (Howell et al, 2004), but not anti-
staphylococcal activity, and it, too, is delivered by LB
secretion (Braff et al, 2004). The biologic importance of
1) Degradation  of corneodesmosomes (serine
proteases)
2) Degradation  of other extracellular species
(acid phosphatase, glycosidases)
Aqueous “Pore” 
formation
Desquamation
Lipid Precursors
glucosylceramides,
cholesterol,
glycerophospholipids,
sphingomyelin
Conversion Into Non-polar Lipid Products
(lipases, glycosidases)
Glucosylceramides Ceramides1–7
Sphingomyelin Ceramides 2,5
Phospholipids FFA
Cholesterol
Catabolic Enzymes
serine proteases, lipases
Other
corneodesmosin,
beta-defensin 2,
acid phosphatase,
glycosidases,
protease inhibitors
STRATUM GRANULOSUM (SG) SG-STRATUM CORNEUM INTERFACE LOWER STRATUM CORNEUM
Cohesion
Barrier function
Antimicrobial
defense
Chemical
defense
Antioxidant
defense
Figure 1
Lamellar body secretion dictates localization of multiple functions to extracellular compartment.
Table I. Protective functions of mammalian stratum corneum
Function Localization
Permeability barriera Extracellular
Cohesion (integrity) ! desquamationa Extracellular
Antimicrobial barrier (innate immunity)a Extracellular
Mechanical (impact and shear resistance) Corneocyte
Toxic chemical/antigen exclusion Extracellular
Selective chemical absorption Extracellular
Hydration Corneocyte
UV barrier Corneocyte
Initiation of inflammation (cytokine activation)a Corneocyte
Psychosensory interface Unknown
Thermal barrier Unknown
aRegulated or thought to be activated by (SC) pH.
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cathelicidins in antimicrobial defense is shown by the
increased incidence of skin infections in knockout mice
(Nizet et al, 2001). Moreover, whereas hBD2 and hCAP-18
levels upregulate in psoriasis, which rarely becomes
secondarily infected, these peptides fail to upregulate in
lesional skin of active atopic dermatitis (AD) (Ong et al,
2002), which correlates with a high cutaneous carriage of S.
aureus in AD. Psoriasis and RNase 7 appear to primarily
protect against fecal-derived gram-negative bacteria (Harder
and Schro¨der, 2002). Because of their overlapping spectra of
activity against different pathogens, the various antimicrobial
peptide families (hBD and hCAP-18) act synergistically in
antimicrobial defense (Gallo and Nizet, 2003; Zaiou et al,
2003). Thus, antimicrobial peptides co-localize both bio-
chemically and topographically to the SC interstices.
Hydration, ultraviolet (UV) ﬁltration, and immunosuppression
are linked through the histidase pathway In addition to re-
sistance of the skin to mechanical or blunt injury, corn-
eocytes (‘‘bricks’’) generate filaggrin-derived peptides and
their deiminated products, which, along with sebaceous
gland-derived glycerol (Fluhr et al, 2003), regulate not only
SC hydration but also several other downstream functions
(Fig 2). Early in cornification, filaggrin, the predominant,
histidine-enriched, basic protein in F-type keratohyalin
granules, disperses around keratin filaments within the
stratum compactum (Dale et al, 1997). At ambient humidi-
ties (o85% RH), i.e., above the stratum compactum, filag-
grin is largely hydrolyzed by a still-uncharacterized,
cytosolic protease into free amino acids, including histi-
dine, glutamine (glutamic acid), and arginine (Scott and
Harding, 1986; Harding et al, 2000). These amino acids, and
their distal, deinminated products (urocanic acid, pyrroli-
done carboxylic acid, and ornithine/citrulline/aspartic acid,
respectively) comprise much of the osmotically active ma-
terial that regulates SC hydration (Harding et al, 2000). His-
tidine is deiminated enzymatically to its acidic, polar,
plurifunctional metabolite, trans-urocanic acid (tUCA), by
the enzyme, histidine ammonia lyase (histidase) (Scott,
1981). As it acts as an endogenous sunscreen, tUCA is
photoisomerized by UV-B to cUCA (De Simone et al, 2001),
a potent immunosuppressive molecule, implicated in the
pathogenesis of UV-induced skin cancers (Noonan and De
Fabo, 1992; Finlay-Jones and Hart, 1998). Thus, products of
the histidase pathway regulate two key defensive functions
as well as a pathophysiologic function of the SC.
Multiple defensive functions can be altered by
a single stressor
Relationship of psychological stress to barrier function and
SC integrity/cohesion Some key SC functions can be co-
regulated in response to single common stressors. A per-
tinent example is psychological stress, which exerts nega-
tive effects not only on permeability barrier homeostasis
(Denda et al, 2000; Altemus et al, 2001; Garg et al, 2001) but
also on SC integrity and cohesion. Stress impacts these
functions by a common mechanism, i.e., an increase in en-
dogenous glucocorticoids (Denda et al, 2000), and gluco-
corticoids, in turn, alter barrier function and SC integrity/
cohesion by a common mechanism, i.e., suppression of
epidermal lipid synthesis and LB production (Kao et al,
2003). Accordingly, not only the stress-induced barrier ab-
normality, but also the abnormality in SC integrity can be
reversed (overridden) by a mixture of physiologic lipids,
containing all three key SC species (i.e., ceramides, FFA,
and cholesterol) (Kao et al, 2003).
Impact of pH on multiple defensive functions A second
example of a common stressor that modulates multiple
functions is SC pH. In fact, pH orchestrates at least three
important SC defensive functions (Table I). Using a flat sur-
face electrode, the pH of mammalian SC typically ranges
from 4.5 to 5.0 in the outer SC, approaching neutrality in the
lower SC (Ohman and Vahlquist, 1994). Recent studies,
utilizing fluorescence-lifetime imaging (FLIM) combined with
mutliphoton microscopy, show that SC pH is heterogene-
ously distributed, and that the pH gradient is non-linear
(Behne et al, 2002, 2003). Most importantly, FLIM demon-
strated that membrane domains even at the level of the
stratum granulosum (SG)–SC interface are selectively acid-
ified (Behne et al, 2002).
Although at least two endogenous, biochemical path-
ways regulate SC pH, the full array of functions that are
impacted by each mechanism is still largely unclear. A
third mechanism is the histidine-to-UCA pathway, which
can account quantitatively for SC acidification (Krien and
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Functions potentially impacted by filaggrin metabolism in the stratum corneum.
STRATUM CORNEUM DEFENSIVE FUNCTIONS 185125 : 2 AUGUST 2005
Kermici, 2000), but its importance is unclear, because:
(1) This mechanism would be inoperative in the fully hy-
drated inner SC (Scott and Harding, 1986; Bouwstra et al,
2003). (2) Because tUCA is extremely polar, it might not in-
fluence pH within the relatively hydrophobic, extracellular
membrane domains. (3) UCA levels peak immediately after
birth, following initial exposure of neonatal SC to a dry en-
vironment (Scott and Harding, 1986; Fluhr et al, 2004), but
acidification of human SC develops much more slowly, i.e.,
over several weeks to months (Giusti et al, 2001). (4) Pa-
tients and mice with histidinemia (histidase mutations) ex-
hibit no known abnormalities in skin morphology, or
function (Fluhr et al, 2004). Thus, other acidifying mecha-
nisms probably predominate as SC acidifying mechanisms.
Phospholipid (PL)-to-FFA hydrolysis by an as yet incom-
pletely characterized extracellular secretory phospholipases
(sPLA2) clearly influences SC pH (Fluhr et al, 2001). sPLA2
represent a growing family of non-polar lipids of homologous
enzymes of low molecular mass (13–18 kDa) that catalyze
the hydrolysis of glycerophospholipids at the sn-2 position,
generating FFA and lysophospholipids (Redoules et al, 1999;
Maury et al, 2000; Schadow et al, 2001). Whereas the ep-
idermis expresses several sPLA2 isoforms, i.e., groups I, II,
and group X sPLA2 (Maury et al, 2000; Schadow et al, 2001),
only the group I isoform is known to persist into the SC
(Redoules et al, 1999; Maury et al, 2000; Mazereeuw-Hautier
et al, 2000). Like its PL substrates, sPLA2 activity localizes to
LB, which deliver the enzyme to the SC interstices (Grayson
et al, 1985; Elias et al, 1988). sPLA2-mediated hydrolysis of
PL generates not only FFA that are required as structural
components of the SC extracellular lamellar bilayers (Mao-
Qiang et al, 1995b; Mao-Qiang et al, 1996), but also protons
that impact at least two SC defensive functions (Fluhr et al,
2001). When sPLA2 activity is blocked, SC pH increases,
producing abnormalities in both barrier function and SC in-
tegrity/cohesion (Fluhr et al, 2001). Although altered SC in-
tegrity/cohesion is linked to premature dissolution of CD,
paralleled by reduced desmoglein 1 (DSG1), the alterations
in barrier homeostasis are linked not only to depletion of
FFA, but also to downstream deactivation of b-GlcCer’ase
and acidic sphingomyelinase (aSMase) activities (Mauro
et al, 1998; Fluhr et al, 2001; Hachem et al, in press). Thus,
acidification blockade has downstream consequences for
lipid-processing enzymes with acidic pH optima.
Non-energy requiring, integral membrane transporters
that extrude protons in exchange for sodium–proton ex-
changer (NHE) comprise at least six 80–90 kDa gene prod-
ucts, with 35%–60% homology (Orlowski and Grinstein,
1997). Whereas NHE2–5 are present in extracutaneous tis-
sues, NHE1 is expressed ubiquitously, including in keratin-
ocytes/epidermis (van Hooijdonk et al, 1997; Behne et al,
2001; Sarangarajan et al, 2001), where it localizes to the
outer nucleated cell layers of the epidermis (Behne et al,
2001). Both k.o. and NHE1 inhibitor-treated mice reveal an
increase in SC pH ( 1/3 pH unit), and delayed barrier re-
covery after acute abrogations (Behne et al, 2001). Because
NHE1 k.o. mice reveal a selective increase in pH in mem-
brane domains in the lower SC, and NHE1 is inserted into
the apical plasma membrane of SG cells, it appears to se-
lectively acidify extracellular domains just above the SG–SC
interface (Behne et al, 2002, 2003).
The prevalent hypothesis about the principal role for SC
pH is its putative importance for antimicrobial defense (Aly
et al, 1978). The microflora of the skin comprise: (a) tran-
sient, (b) temporary-resident, and (c) permanent-resident
species (Leyden et al, 1979), including coagulase-negative
staphylococci, which prevail on dry surfaces, whereas Pro-
pionibacteriae predominate on sebaceous gland-enriched
skin sites. These normal flora grow best at a more acidic
pH, whereas pathogenic bacteria, such as S. aureus, grow
best at a neutral pH (Korting et al, 1990). The importance of
pH for antimicrobial function is further suggested by neo-
natal, eczematous, and atopic skin, which display a neutral
pH (Sparuvigna et al, 1999; Visscher et al, 2000; Giusti et al,
2001), coupled with an enhanced risk of infection (Beare
et al, 1958; Yosipovitch et al, 1993; Fluhr et al, 2004). As
compelling as these data are, the role of the acidic pH in
antimicrobial defense has not been demonstrated directly.
The importance of SC pH for permeability barrier home-
ostasis is suggested both by the worsening of barrier func-
tion when intact skin is exposed to an alkaline pH (Thune
et al, 1988), and by the delay in barrier recovery that occurs
when perturbed skin is exposed to a neutral pH (Mauro
et al, 1998; Hachem et al, 2003). pH influences barrier
function directly through its effects on membrane bilayer
organization (Bouwsta et al, 2000), and/or secondarily
through its regulation of extracellular lipid processing
(Fig 1). Although b-GlcCer’ase and aSMase exhibit acidic
pH optima, sPLA2 and steroid sulfatase (SSase) display
neutral-to-alkaline pH optima, suggesting that sequential
changes in SC pH within microenvironments of the SC in-
terstices orchestrate lipid processing (Fig 1).
Integrity/cohesion, which is inversely related to rates of
corneocyte shedding (desquamation), represents a second
SC function that is pH dependent. Although a large family of
SP are present in SC, two SP, the epidermis-specific SC
chymotryptic (SCCE) and SC tryptic (SCTE) SP, (kalleikreins
5 and 7) appear to be critical mediators of this function.
Because SCCE and SCTE exhibit neutral-to-alkaline pH
optima (Brattsand and Egelrud, 1999; Hanson et al, 2002),
they would exhibit higher activities when SC pH increases,
as in inflammatory dermatoses. But SP could sustain low
rates of normal desquamation even in normal SC, because
these enzymes exhibit residual activity against physiologic
substances, even at an acidic pH (Caubert et al, 2004),
where aspartate and cysteine proteases, with acidic pH
optima, could also become operative (Fig 3). In contrast, it
is likely that SCCE/SCTE activities dominate at all levels of
Outer SC
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SCCP
Cath D
SCCE
SCTE
pH
5.0
7.0
Normal Dermatitic
pH
7.0
7.0
SCTE, SCCE
SCTE, SCCE
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Figure3
Proposed pH-dependent role of different desquamatory proteases in
normal and dermatitic skin. SCCE and SCTE, see text; Cath D, ca-
thepsin D; SCCP, SC cysteine protease.
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SC in pathological skin, which is characterized by optimal
conditions for SP activation (i.e., increased pH, hydration,
and Ca2þ levels).
Perturbations of one defensive function can alter
other key functions
Humidity (SC hydration) inﬂuences permeability barrier. The
interactivity of certain defensive functions is further dem-
onstrated by the changes in permeability barrier function
that follow changes in external humidity. Whereas sustained
exposure to a physiologically relevant humid environment
(85% RH) downregulates barrier competence, prolonged
exposure of normal skin to low ambient humidities (below
20% RH) enhances barrier homeostasis (Denda et al, 1998)
(Fig 6). Thus, hydration stimulates appropriate alterations in
barrier function. Yet, more extreme switches in hydration,
i.e., from skin previously exposed to a humid to a dry
environment, paradoxically produce a profound, though
temporary, deficit in barrier function (Sato et al, 2002) (Fig 4).
Apparently humid-adapted granular cells cannot upregulate
their metabolic and secretory machinery. The relevance of
this work for humans, who often travel between such ex-
tremes in humidity, is unclear. Fortunately, the barrier defect
is temporary, as defective cells are quickly replaced by new,
functionally competent arrivals to the SG (Sato et al, 2002).
Key mechanical structures regulate permeability barrier An-
other pertinent example of one function impacting a second
is shown by the role of the cornified envelope (CE) not only
as a mechanical barrier, but also as a scaffold that organizes
secreted extracellular lipids into the continuous lamellar
membrane structures, which mediate permeability barrier
function. Defective lamellar structures and increased trans-
cutaneous water loss occur in both transglutaminase 1
(TG1)-deficient lamellar ichthyosis (LI) (Lavrijsen et al, 1995;
Elias et al, 2002c) and loricrin keratoderma (Vohwinkel’s
disease) (Schmuth et al, 2004b), when an attenuated or
fragile CE is associated with abnormalities in adjacent
lamellar membranes, in turn provoking altered barrier
function.
Permeability barrier disruption initiates inﬂammation Current
fashion views the skin as a proinflammatory tissue (e.g.,
distinctive T cell abnormalities occur in common de-
rmatoses, such as psoriasis, contact dermatitis, and AD).
Yet, these diseases are often initiated and sustained by ex-
ternal perturbations (e.g. Koebner phenomenon in psoria-
sis). It appears increasingly likely that cutaneous immune
phenomena can be triggered by both the release of a pre-
formed pool of primary cytokines, IL-1a, IL-1b, and TNFa,
from the corneocyte and granular cell cytosol, as well as
increased production of these cytokines, in response to
minimal external (barrier) perturbations (Elias and Feingold,
1999, 2003). Following their release, these cytokines signal
divergent, downstream pathways that initiate both homeo-
static (repair-related) and pro-inflammatory processes, re-
storing barrier competence while at the same time initiating
a signal cascade that stimulates cutaneous inflammation by
downstream recruitment/entrapment of inflammatory cells.
According to this ‘‘outside–inside’’ perspective, many cuta-
neous inflammatory phenomena, including disease-specific
T cell responses, are recruited primarily as incidental par-
ticipants in a defensive sequence aimed at normalizing SC
function. Thus, barrier function and inflammatory signaling
are linked, defensive functions of the epidermis.
Structural and Biochemical Basis for
the SC Barrier
Epidermal differentiation leads to the formation of the SC, a
heterogeneous tissue composed of lipid-depleted corn-
eocytes embedded in a lipid-enriched extracellular matrix,
which subserves the barrier. These lipids derive from a
highly active, lipid-synthetic factory, operative in all of the
nucleated cell layers of the epidermis (Feingold, 1991),
which generates a unique lipid and hydrolase-enriched, se-
cretory organelle, the epidermal LB (Odland and Holbrook,
1981; Landmann, 1988). LB are 0.30.4  0.25 mm struc-
tures, which comprise about 10% of the cytosol of the SG
(Elias et al, 1977a, 1998a). Following secretion of their con-
tents at the SG–SC interface, LB contents are processed
from a polar lipid mixture into a hydrophobic mixture of
ceramides, ‘‘FFA’’, and cholesterol, organized into the la-
mellar membranes that form the hydrophobic matrix within
which corneocytes are embedded (Elias and Menon, 1991).
The corneocyte Although corneocyte proteins have been
studied intensively as markers of epidermal differentiation
(Eckert et al, 1997), their role in the permeability barrier is
less clear. Yet, these anucleated cells are well known to
perform other critical epidermal functions (Table I). The
corneocytes influence the permeability barrier through their
function as ‘‘spacers’’, i.e., they force water and xenobiotes
to traverse a tortuous, extracellular hydrophobic pathway
(Potts and Francoeur, 1990), and by serving as a scaffold for
lamellar membrane organization.
Proteins of the CE The CE, and its external, ceramide-en-
riched, cornified-bound lipid envelope (CLE) together pro-
vide a stable, mechanically and chemically resistant
scaffold for the deposition and organization of the extra-
cellular matrix (Hohl, 1990). The CE, a uniform, 15 nm thick,
peripheral envelope that encloses the corneocyte cytosol
(Hohl, 1990; Ishida-Yamamoto and Iizuka, 1998), consists of
several highly cross-linked, cytosolic proteins, including in-
volucrin, loricrin, elafin, desmoplakin, envoplakin, cytosta-
tins, and pancornulins/cornifins (small proline-rich proteins)
(Hohl et al, 1991; Steinert and Marekov, 1997).
Involucrin, a 68 kDa rod-shaped molecule with a series of
highly conserved 10 amino acid repeats, containing 3 gluta-
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 barrier
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Figure 4
Changes in external humidity alter permeability barrier function.
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mine residues each as potential cross-linking sites (Steinert
and Marekov, 1997), accounts for 5%–15% of the CE ex-
pressed in the late spinous and SG layer, and it appears to
be the first envelope precursor that is cross-linked by TG1,
and therefore localizes to the outer SG. Loricrin is a cysteine
(7%), serine (22%), and glycine (55%) enriched, 38 kDa,
highly insoluble peptide, comprising one component of
keratohyalin granules (Hohl et al, 1991), and accounts for up
to 80% of CE mass. Loricrin is cross-linked into the CE late
in differentiation, i.e., immediately after LB secretion (Bic-
kenbach et al, 1995). A mutation resulting in elongation of
the C-terminal domain of one loricrin allele occurs in some
kindreds with Vohwinkle’s keratoderma (Maestrini et al,
1996). These patients display not only digital constrictions
(pseudo-ainhum) and a dense, honeycomb keratoderma,
but also a mild, generalized ichthyosis, and a permeability
barrier abnormality, as in LI (Schmuth et al, 2004b).
Formation of the CE is catalyzed largely by the epider-
mal-specific, calcium-dependent enzyme, TG1, a 92 kDa
protein, which forms g-glutamyl-E-lysine isopeptide bonds
between constituent CE proteins (Hennings et al, 1981;
Eckert et al, 1997; Kalinin et al, 2002). Although TG1 mRNA
is expressed in lower layers, the enzyme becomes active
after membrane anchorage to the outermost granular cell
(Chakravarty and Rice, 1989), coinciding with the calcium
(Ca) gradient peaks in the outer epidermis (Menon et al,
1985a, b), and with activation by an aspartate protease,
cathepsin D (Egberts et al, 2004). At least two other TG
isoforms, TG2 (82 kDa) and TG3 (77 kDa), contribute var-
iably to CE cross-linking (Kalinin et al, 2002). Yet, because
the CE from corneocytes of patients with LI is invariably
defective, residual TG2 and 3 activities cannot compensate
completely for TG1 deficiency (Hohl et al, 1993; Elias et al,
2002c). Whereas autosomal recessive forms of primary
ichthyosis comprise a heterogeneous group, patients with
the severe, classic LI phenotype typically display TG1 de-
ficiency (Huber et al, 1995), whereas patients with less se-
vere phenotypes reflect a variety of genotypes, including
TG1 deficiency (Choate et al, 1996b, 1998). LI patients dis-
play a severe permeability barrier abnormality (Lavrijsen
et al, 1995; Choate et al, 1996a, b; Elias et al, 2002c), but
despite the attenuated CE in TG1-deficient LI, increase in
permeability occurs through the SC interstices (Elias and
Ghadially, 2002). Although the extracellular membranes in LI
display minor abnormalities in interlamellar spacing (Ghadi-
ally et al, 1992b; Lavrijsen et al, 1995), the basis for in-
creased intercellular permeability is best explained by the
fragmentation of extracellular lamellae that occurs in these
patients (Elias and Ghadially, 2002).
Finally, CE-associated proteins, while being necessary
for the steady-state maintenance of normal barrier home-
ostasis, are transiently downregulated following acute bar-
rier perturbations, apparently as a form of metabolic
conservation (Elias et al, 2002b) (Fig 4), but subsequently
upregulated during later stages of barrier recovery (Ekana-
yake-Mudiyanselage et al, 1998).
Structural proteins of the corneocyte cytosol. Keratins are
the most abundant structural proteins of the epidermis and
its appendages, contributing to the mechanical properties
of these epithelia (Fuchs and Weber, 1994). Keratins are of
two types, type l or acidic (K9–20) and type II or basic (K1–
8), which are co-expressed in pairs, and all keratins display
a similar secondary structure, with a central, rod domain
comprising four a helices, and distinctive, non-helical, head
and tail sequences (Kalinin et al, 2002). Whereas K5 and 14
are expressed in the basal layer, K1, 2e, and 10 are ex-
pressed in suprabasal layers, eventually accounting for
80% of the mass of the corneocyte (Fuchs, 1994; Fuchs
and Weber, 1994; Eckert et al, 1997). Deletions of as few as
10 amino acids from the rod domain of either K1, 2e, or 10
result in keratin clumping, i.e., the defective allelic protein
binds to its partner in a dominant-negative fashion, forming
defective intermediate filaments, resulting in several forms
of epidermolytic hyperkeratosis (EHK) (Rothnagel et al,
1992; Corden and McLean, 1996), which shift from
predominantly blistering in neonates to predominantly
hyperkeratosis after exposure to the xeric, post-natal envi-
ronment (Williams and Elias, 1993). The basis for the per-
meability barrier abnormality in EHK results from the
cytoskeleton abnormality: rather than simply producing
corneocyte fragility, the abnormal keratin pairs interfere
with LB secretion, resulting in decreased amounts of ex-
tracellular lipids (Schmuth et al, 2001b).
Type II keratin filaments and their partners attach co-
valently to the CE via a single lysine residue in a highly
conserved region of the VI subdomain of Kl (Kimonis et al,
1994). Accordingly, mutations in the Vl domain, affecting a
highly conserved lysine residue, interfere with the insertion
of type II keratins to desmoplakin in the CE (Kimonis et al,
1994). These patients display a diffuse, non-epidermolytic
palmo-plantar keratoderma (NSPPK) with acral keratotic
plaques (Candi et al, 1998). Detachment and retraction of
keratin bundles from CD in the SC result in both micro-
vesiculation and deformation of the keratinocyte periphery
(Candi et al, 1998) (i.e., corneocytes do not flatten properly).
Proﬁlaggrin is a large, histidine-rich, highly cationic
phosphoprotein, consisting of 37 kDa filaggrin repeats,
connected by peptide segments enriched in hydrophobic
amino acids (Fleckman et al, 1985). Profilaggrin is concen-
trated within keratohyalin granules, where it may sequester
loricrin, which also localizes to keratohyalin. During terminal
differentiation, profilaggrin is both dephosphorylated and
proteolytically processed by a Ca2þ -dependent protein
convertase, furin, at the N-terminus to yield filaggrin (Resing
et al, 1993), which ionically binds to Kl/l0, inducing the for-
mation of macrofibrils in the corneocyte cytosol (Dale et al,
1997). Immunolocalization studies suggest that processed
filaggrin peptides initially associate via their N-terminal
domain with the CE in the lower SC, but filaggrin later
detaches, allowing proteolysis into hygroscopically active
amino acids and their deiminated products.
Extracellular lipids of the SC The processing of secreted
LB contents leads to the progressive generation of a mix-
ture of relatively non-polar lipids, which is enriched in
ceramides, cholesterol, and FFA, present in an approxi-
mately equimolar ratio (Schurer and Elias, 1991). Lesser,
but variable amounts of cholesterol esters, triglycerides,
and diglycerides, which may, in part, be of sebaceous gland
origin, also persist. The FFA comprise a mixture of essential
(EFA) and non-essential FFA (NEFA) (Lampe et al, 1983), and
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both are required separately as critical structural ingredients
of the barrier (Schurer and Elias, 1991). NEFA derive largely,
if not entirely, from the hydrolysis of PL, which are co-se-
creted with their respective sPLA at the SG–SC interface
(Elias et al, 1988; Mao-Qiang et al, 1995b; Mao-Qiang et al,
1996), which also results in acidification of the SC interstic-
es (Fluhr et al, 2001).
The ‘‘mortar’’ lipids also contain abundant cholesterol,
which is secreted unchanged from LB; lesser quantities of
cholesterol derive from the hydrolysis of cholesterol sulfate
to cholesterol by the enzyme, steroid sulfatase (Elias et al,
2004). Although a variety of studies have shown that cho-
lesterol is critical for permeability barrier function (e.g., Fe-
ingold et al, 1990), cholesterol derived from cholesterol
sulfate is not required (Zettersten et al, 1998).
A third, key lipid constituent of the mortar is a family of
nine ceramide species (Fig 1), which vary according to their
(Wertz et al, 1984): (1) sphingosine versus phytosphingosine
(extra-OH group) base; (2) a- versus non-a-hydroxylated
N-acyl fatty acids, which typically are 4C30 in length; and
(3) the presence of an additional, o-esterified linoleic acid
residue. Whereas all nine ceramides are generated from
their glucosyl/ceramide precursors, only ceramides 2 and 5
derive from sphingomyelin (Uchida et al, 2000). Ceramides
1, 4, and 7 are the principal repositories for the essential
fatty acid (EFA), linoleic acid, a critical structural ingredient
in the barrier (Elias and Brown, 1978; Elias et al, 1980).
These epidermis-unique molecules appear to link adjacent
bilayers through their highly elongated N-acyl chains, with
o-esterified linoleic acid (Bouwstra et al, 1998). The esteri-
fied linoleate moiety is important for barrier function, be-
cause in EFA deficiency, the primary biochemical defect is
a substitution of NEFA for linoleic acid, a biochemical al-
teration that results in a pronounced permeability barrier
defect (Elias et al, 1980).
CLE. A 10 nm, tightly apposed, electron-lucent, plasma
membrane-like structure, now termed the CLE, replaces the
plasma membrane on the external aspect of mammalian
corneocytes (Swartzendruber et al, 1987; Marekov and Ste-
inert, 1998). After aggressive solvent treatment (e.g., chlo-
roform:methanol extraction), the CLE appears to comprise a
single, outer electron-dense leaflet, separated from the CE
by an electron-lucent space (Swartzendruber et al, 1987).
But following treatment with the polar solvent, pyridine, the
CLE instead can be seen to comprise a trilaminar structure,
intimately related to the CE (Elias et al, 1977a, 2000, 2002c).
Involucrin, a major constituent of outer portion of the CE, is
cross-linked prior to cornification, forming a scaffold for
CLE formation (Steinert and Marekov, 1997). The CLE com-
prises o-hydroxyceramides (Cer), with very long-chain, N-
acyl fatty acids, covalently bound to the CE (Swartzendru-
ber et al, 1987; Marekov and Steinert, 1998). These
o-hydroxy derive from insertion of the b-glucosyl o-
hydroxyceramide-enriched limiting membrane of the LB in-
to the apical plasma membrane of the outermost granular
(SG) cells (Wertz et al, 1989; Behne et al, 2000). Bound
glucosyl-b-hydroxy ceramides, however, are quickly deglu-
cosylated (Doering et al, 1999). The CLE could serve: (1) as
a ‘‘molecular rivet’’ in SC cohesion (Wertz et al, 1989); and
(2) as a scaffold for extracellular lamellar membrane organ-
ization (Elias and Ghadially, 2002; Schmuth et al, 2004a–c).
Yet, despite its extreme hydrophobicity, its ability to restrict
water movement is unclear, because solvent extraction of
SC leaves the CLE largely intact, whereas the SC becomes
porous to transcutaneous water loss (Elias et al, 2000). Yet,
the CLE could still restrict water movement to extracellular
domains, while limiting both water uptake into the corn-
eocyte, and egress of water-soluble, hygroscopic amino
acids out of the corneocyte cytosol (Elias et al, 2000).
Metabolic Regulation of Permeablity
Barrier Homeostasis
Although the SC has many functions, its ability is to serve
as a protective barrier that prevents excess loss of fluids
and electrolytes, allows life in a terrestrial environment
(Scheuplein and Blank, 1971). As noted above, the perme-
ability barrier is mediated by the organization of the extra-
cellular lipids of the SC into a series of parallel membrane
structures, and its distinctive composition (Elias and
Menon, 1991).
Dynamics of barrier recovery. The ‘‘cutaneous stress
test’’ comprises any type of acute barrier disruption (organic
solvent, detergent, tape stripping) that depletes the SC of its
complement of lipids (Feingold, 1991; Elias and Feingold,
1992). Although the total time required for barrier recovery
varies according to age and species, there is always an
initial, rapid recovery phase, followed by a prolonged re-
covery phase that requires about 35 h for completion in
rodents (Grubauer et al, 1989). In young humans, the acute
recovery phase is somewhat longer (about 12 h), and the
later recovery phase is prolonged to 72 h, but in aged hu-
mans, the recovery phase can last over 1 wk (Ghadially et al,
1995). Restoration of barrier function is accompanied by re-
accumulation of lipids within the SC interstices, visible with
Nile red fluorescence, and by the reappearance of lamellar
membranes, as early as 2 h after acute disruption (Grubauer
et al, 1987, 1989). Because artificial restoration of the barrier
with a vapor-impermeable, but not vapor-permeable mem-
brane, inhibits barrier recovery and all attendant metabolic
processes (Grubauer et al, 1989), the entire metabolic re-
sponse is aimed specifically at normalization of barrier
function (Feingold, 1991; Elias and Feingold, 1992).
The same test can also be deployed as a physiologic
challenge (i.e., stress test) that can discern abnormal func-
tion, even when basal parameters are normal. Thus, the
cutaneous stress test is analogous to other clinical mane-
uvers used to identify pathology (e.g., cardiac treadmill ex-
am, end respiratory volume, overnight water deprivation,
etc.). Indeed, the cutaneous stress test revealed deficient
barrier function in both aged (Ghadially et al, 1995) and
neonatal skin (Fluhr et al, 2004), despite deceptively normal
function under basal conditions. Moreover, psychologic
stress results in a delay in barrier recovery (Denda et al,
2000; Altemus et al, 2001; Garg et al, 2001), and it amplifies
differences in barrier function among still other ‘‘normal’’
groups, such as individuals with type 1 vs. type 4–5
pigmentation, and in testosterone-replete males (Elias and
Feingold, 2003). Although clinicians have not yet exploited
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the stress test as a clinical tool, these results explain
the propensity for inflammatory dermatoses to be more se-
vere in males than in females, and for fair-skinned individ-
uals to have ‘‘sensitive’’ (? atopic) skin.
LB secretion leading to lamellar membrane forma-
tion The first step in the repair response following barrier
disruption is rapid secretion (within minutes) of performed
LB contents from cells of the outer SG, which leaves the
cytosol of these cells largely devoid of LB (Menon et al,
1992; Elias et al, 1998a). Newly formed LB then begin to
reappear in SG cells by 30–60 min, and by 3–6 h the number
(density) of LB in SG cells exceeds normal. Because of ac-
celerated secretion and organellogenesis between 30 min
and 6 h, the quantities of secreted LB contents increase at
the SG–SC interface, and by 2 h new, lipid-enriched lamellar
bilayers begin to appear in the lower SC (Grubauer et al,
1989; Menon et al, 1992). Thus, the exocytosis of LB pro-
vides a pathway by which the epidermis delivers lipids and
their respective lipid-processing enzymes simultaneously to
the extracellular spaces of the SC (Fig 1).
Structural adaptations of the outermost granular cell
that facilitate secretion. Although LB secretion remains
largely restricted to the outermost SG cell (Menon et al,
1992; Elias et al, 1998a), certain structural features of the
SG cell facilitate delivery of LB-derived lipid and enzyme
contents to the SG–SC interface, designating the outermost
SG cell as the ‘‘secretory granulocyte’’ (Elias et al, 1998a):
(1) a highly disbursed, tubulo-reticular trans-Golgi network
that extends throughout the apical cytosol (see also Mad-
ison et al, 1998); (2) deep invaginations of the SG–SC in-
terface that form an extensive honeycomb/latticework, and
are continuous with the intercellular domains; and (3) arrays
of contiguous LB that undergo compound exocytosis (or-
ganelle-to-organelle, rather than solely organelle-to-plasma
membrane fusion) following acute perturbations. Together,
these specialized structures explain the ability of the out-
ermost SG cell to function as a secretory cell, despite being
both heavily keratinized and in possession of a partially de-
veloped CE (Elias et al, 1998a). Although others have inter-
preted images of the investigations quite differently; i.e.,
that the invaginations reflect a non-energy-requiring unfurl-
ing (continuous phase from LB to the lamellar membranes)
of lipids (Norlen, 2001a, b), this hypothesis contradicts the
large body of evidence that LB assembly and secretion are
highly regulated processes that can be blocked by inhibitors
or by exposure to low temperatures that slow energy-re-
quiring functions.
Regulation of lipid synthesis by barrier require-
ments. The rapid formation of LB following acute barrier
disruption requires increased availability of the major lipid
components of LB, i.e., cholesterol, glucosylceramides, and
PL (Feingold, 1991; Elias and Feingold, 1992). Although the
epidermis is a very active site of lipid synthesis under basal
conditions (Feingold et al, 1983), barrier disruption stimu-
lates a further increase in the synthesis of cholesterol,
ceramides, and FA (a major component of both PL and
ceramides) (Feingold et al, 1983; Menon et al, 1985a, b;
Proksch et al, 1990; Holleran et al, 1991a) (Fig 6). The in-
crease in cholesterol synthesis is associated with an in-
crease in the activity, protein levels, and mRNA levels of
HMG CoA reductase (Proksch et al, 1990; Harris et al,
1997), and other key enzymes in the cholesterol synthetic
pathway; i.e., HMG CoA synthase, farnesyl diphosphate
synthase, and squalene synthase (Fig 6) (Harris et al, 1997).
Whereas the increase in FA synthesis occurs because of an
increase in the activity and mRNA levels of both of the key
enzymes of FA synthesis, acetyl CoA carboxylase, and FA
synthase (Ottey et al, 1995), the increase in ceramide syn-
thesis is because of an increase in the activity and mRNA
levels of serine palmitoyl transferase (SPT) (Holleran et al,
1991a) (Fig 6), the enzyme which catalyzes the first com-
mitted step in ceramide synthesis. In contrast, gluco-
sylceramide synthase, the enzyme which synthesizes
glucosylceramides, does not increase following barrier dis-
ruption (Chujor et al, 1998). But glucosylceramide synthesis
could still be dependent upon the availability of FA for both
sphingoid base formation and N-acylation. Thus, a specific,
coordinate increase in the synthesis of the key lipid con-
stituents of LB provides the pool of lipids, required for the
formation of new LB.
Barrier homeostasis requires synthesis of each of the
three key lipids Using specific inhibitors of key synthetic
enzymes, cholesterol, FA, ceramide, and glucosylceramide
synthesis were shown to be individually required for barrier
formation (Feingold et al, 1990; Holleran et al, 1991b; Mao-
Qiang et al, 1993a; Chujor et al, 1998). For example, block-
ade of cholesterol synthesis with topical inhibitors of HMG
CoA reductase (e.g., statins) slows barrier recovery and se-
lectively delays the return of cholesterol to the SC (Feingold
et al, 1990, 1991). These effects are because of a specific
block in cholesterol synthesis, because co-applications of
either mevalonate or cholesterol (distal products) normalize
barrier recovery. Likewise, topical 5-(tetradecyloxy)-2-fur-
ancarboxylic acid (TOFA), an inhibitor of acetyl CoA car-
boxylase, one of the two key enzymes of FA synthesis,
inhibits epidermal FA synthesis and delays barrier repair
(Man et al, 1993; Mao-Qiang et al, 1993a). Yet, TOFA-in-
duced inhibition of barrier repair again can be overcome by
topical co-applications of enzyme product (i.e., FFA), again
demonstrating the specificity of the inhibitor. Moreover, b-
chloroalanine, a selective inhibitor of SPT, also delays barrier
recovery after acute barrier disruption (Holleran et al, 1991b),
and again, inhibition of barrier recovery can be overcome by
co-applications of exogenous ceramides. Finally, PDMP, a
selective inhibitor of glucosylceramide synthase (GC synt-
hase), also inhibits barrier recovery after acute disruption
(Chujor et al, 1998). Inhibition of each of these enzymes
produces a similar result: decreased LB formation, contents,
and secretion, as well as a paucity of extracellular lamellar
bilayers (Feingold, 1991; Elias and Feingold, 1992). These
studies clearly demonstrate that epidermal cholesterol, FA,
ceramide, and glucosylceramide synthesis are required in-
dividually for LB formation and barrier homeostasis.
The key SC lipids are required in an equimolar distribu-
tion. Whereas the above-described studies clearly demon-
strate the individual requirement for each of the three key
lipids (cholesterol, FA, and ceramides) for the permeability
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barrier, these lipids must be supplied together in a proper
proportion for normal barrier recovery in rodents and humans
(Man et al, 1993, 1996). Topical applications of any one or
two of the three key lipids to acutely perturbed skin actually
delays barrier recovery, whereas application of the three key
lipids in an equimolar mixture normalizes recovery rates (Man
et al, 1993, 1996). Both incomplete and complete mixtures of
the three key lipids rapidly traverse the SC, internalize within
the granular cell layer, bypassing the endoplasmic reticulum
and proximal Golgi apparatus, targeting distal sites (i.e., the
trans-Golgi network), where LB are formed (Mao-Qiang et al,
1995a). Within LB, the exogenous and endogenous lipids
mix, producing normal or abnormal LB contents and derived
lamellar membrane structures, depending on the molar dis-
tribution of the applied lipids. Further acceleration of barrier
recovery can be achieved in both rodents and humans by
increasing the proportion of any of the three key lipids to a
3:1:1 ratio (Man et al, 1996; Zettersten et al, 1997). Thus,
physiologic mixtures of topical lipids influence barrier func-
tion, not by occluding of the SC, but rather by contributing to
the lipid pool within SG cells, thereby regulating the contents
of newly generated LB. In contrast, non-physiologic lipids,
like petrolatum, function like vapor-permeable membranes at
the surface of the SC (Ghadially et al, 1992a; Mao-Qiang
et al, 1995a).
The contrasting features of non-physiologic and physio-
logic lipids dictate the clinical settings where each is useful.
Bolstering epidermal barrier status should decrease sus-
ceptibility to the large group of skin diseases that are trig-
gered, sustained, or exacerbated by external perturbations,
such as AD, contact dermatitis, and psoriasis (Elias et al,
1999). All of these diseases are characterized by a barrier
abnormality, and the extent of the barrier abnormality par-
allels clinical severity (Ghadially et al, 1996b; Proksch et al,
2003; Sugarman et al, 2003), hence the recent emergence
of ‘‘barrier repair’’ strategies to decrease the susceptibility
to these disorders. These approaches can be classified into
three subcategories (Elias and Feingold, 2001): (1) optimi-
zed mixtures of the three physiologic lipids (ceramides,
cholesterol, and FFA) in appropriate molar ratios to correct
the targeted disease; (2) one or more non-physiologic lipids
(e.g. petrolatum, lanolin); and (3) dressings, either vapor
permeable, which allow metabolic (repair) processes to
continue in the underlying epidermis, or vapor impermeable,
which shut down metabolic responses in the underlying
epidermis. Thus, we can now choose an appropriate barrier
strategy for a specific clinical indication, based upon knowl-
edge of disease pathogenesis (Elias and Feingold, 2001;
Williams and Elias, 2003) (Table II). For example, AD is
characterized by a global decrease in SC lipids with a steep
reduction in ceramides (Imokawa et al, 1991; Proksch et al,
2003), attributable to increased sphingomyelin/glucosylcer-
amide deacylase activity in affected epidermis (Hara et al,
2000); hence, the apparent utility of a ceramide-dominant
mixture of physiologic lipids in AD (Chamlin et al, 2002). In
contrast, aged and photoaged epidermis exhibits a global
reduction in SC lipids (Ghadially et al, 1995), with a further
decrease in cholesterol synthesis (Ghadially et al, 1996a),
hence, the success of a cholesterol-dominant mixture of
physiological lipids in this setting (Zettersten et al, 1997).
Signals of Barrier Homeostasis
Transcriptional regulation of corneocyte protein expres-
sion by nuclear hormone receptor (NHR) ligands. Mem-
bers of both the Class I and Class II family of NHR influence
epidermal barrier formation, function, and development (Ta-
ble II). At least three ligands (glucocorticoids, estrogens,
and androgens) of the Class I family (receptors for the ster-
oid hormones) regulate permeability barrier development in
fetal skin, as well as barrier homeostasis in adult skin. In
fetal skin both exogenous glucocorticoids and estrogens,
either administered in utero or added directly to fetal skin
explants in organ culture, accelerate the development of a
mature permeability barrier, whereas in contrast, adminis-
tration of androgens retards barrier ontogenesis (Hanley
et al, 1996a, b, 1998). Although the impact of Class I ligands
on barrier function in post-natal skin is less well understood,
normal to supra-normal levels of androgens provoke an
analogous decline in permeability barrier homeostasis in
adult murine and human skin (Kao et al, 2001). Yet, an in-
crease in endogenous glucocorticoids, induced by either
psychological stress (Denda et al, 2000), or systemic ad-
ministration of exogenous steroids (Kao et al, 2003), alters
permeability barrier homeostasis and SC integrity/cohesion.
Table II. Cutaneous effects of class II NHR ligands
Receptor Ligands/activators Fetal barrier development Adult barrier homeostasis Anti-inﬂammatory
Classic
RAR All-trans-retinoic acid None Worse Improves
T3R Triodothyronine (T3) Accelerates ? ?
D3R 1,25(OH)2 vitamin D3 None Worse Improves
Liposensor
PPARa Leukotriene B4, fatty acids, fibrates Accelerate Accelerate Improve
PPARg Prostaglandin J2, troglitazone None None Improve
PPARd Free fatty acids None Accelerate Improve
LXR Oxygenated sterols Accelerate Accelerate Improve
NHR, nuclear hormone receptor; PPAR, peroxisome proliferator activator receptor; LXR, liver X receptor.
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Why certain observations in fetal and post-natal skin (e.g.,
effects of glucocorticoids) diverge is not yet known.
The Class II family of NHR includes receptors for both
well-known ligands, such as thyroid hormone (T3R), retinoic
acid, and 1,25 (OH)2 vitamin D3 (D3R), and a number of
receptors (‘‘liposensors’’), whose activators/ligands are en-
dogenous lipids. The roles of these receptors, which include
the peroxisome proliferator activator receptor (PPAR) and
liver X receptor (LXR) in epidermal function, are currently
being characterized (Table II). The activators for most of
these receptors, e.g., PPARa, PPARa/b, and LXRa/b, in-
clude lipid synthetic intermediates or metabolites, such as
certain FFA, leukotrienes, prostanoids, and oxygenated
sterols (Duplus and Forest, 2002; Fitzgerald et al, 2002).
Because it is likely that increased quantities of sterol and
fatty acid metabolites are generated both during epidermal
development (Hurt et al, 1995), and as co-products of the
increase in lipid synthesis that follows barrier disruption
(Feingold, 1991), processes leading to formation/restoration
of the lipid matrix could also concurrently promote corn-
eocyte protein production (Fig 5). Recent studies have
shown that these liposensor activators accelerate fetal skin
development and induce keratinocyte differentiation (Ha-
nley et al, 1994, 1997; Komuves et al, 1998). By regulating
both the transcription of key corneocyte proteins; e.g., in-
volucrin, loricrin, and TG1 (Hanley et al, 2000a, b), and stim-
ulating epidermal lipid synthesis (Rivier et al, 2000), these
liposensors potentially influence both the ‘‘brick’’ and ‘‘mor-
tar’’ compartments of the barrier (Fig 5). Because these
agents also reverse the barrier abnormalities, epidermal
hyperplasia, and cutaneous inflammation in various animal
models (Komuves et al, 2000; Sheu et al, 2002; Fowler et al,
2003; Ruhl et al, 2003), they hold substantial promise as
therapeutic agents in dermatology (Ellis et al, 2000).
Transcriptional regulation of epidermal lipid synthesis
Cholesterol and FA synthesis. Seminal studies by the
Brown and Goldstein laboratory have demonstrated that
both cholesterol and FA synthesis are feedback regulated
by a group of transcription factors, the sterol regulatory el-
ement binding proteins (SREBP) (Brown and Goldstein,
1998). Two SREBP genes (SREBP-1 and SREBP-2) encode
three proteins: SREBP-1A, SREBP-1C, and SREBP-2
(Smith et al, 1988; Vallett et al, 1996). These tripartite pro-
teins, which are  1150 amino acids in length, with a
 480 amino acid NH2-terminal segment facing the cyto-
sol, are members of the basic–helix–loop–helix–leucine zip-
per family of transcription factors. This NH2-terminal
segment is followed by a membrane attachment fragment
of  80 amino acids, containing two membrane-spanning
sequences separated by a  31 amino acid hydrophilic
loop tat projects into the lumen of the ER and nuclear en-
velope, and a COOH-terminal segment of  590 amino
acids that projects into the cytosol. A novel sensing mech-
anism is activated by sterol depletion (Loewen and Levine,
2002; Rawson, 2003). A two-step proteolytic process oc-
curs that results in the release of the NH2-terminal seg-
ments, allowing them to enter the nucleus, where they bind
as homodimers to cis-elements in the promoters of multiple
SREBP-responsive genes stimulating various enzymes of
cholesterol and FA synthesis (Vallett et al, 1996; Brown and
Goldstein, 1998). In contrast, when excess cholesterol ac-
cumulates, proteolytic cleavage is inhibited and transcrip-
tion of target genes declines (Loewen and Levine, 2002;
Rawson, 2003). The two-step cleavage process leading to
the release of active SREBP begins at site 1, between the
Leu and Ser of the RSVLS sequence, in the middle of the
hydrophilic loop (Vallett et al, 1996). The site 1 protease
(S1P) is a SP that splits the lumenal loop of SREBP into two
halves that remain attached by their membrane attachment
domains. Because the S1P localizes to the Golgi, cleavage
of SREBP is initiated there. Transport of SREBP from the
endoplasmic reticulum to the Golgi is facilitated by SREBP
cleavage-activating protein (SCAP), an elongated protein
whose COOH terminus complexes with the COOH-terminus
of SREBP (Rawson, 2003). The final release of the active
NH2 fragment of SREBP requires a second proteolytic step
at Site 2, a Leu–Cys bond at the border of the cytosolic and
membrane portion of the NH2 segment. Although the Site 2
protease (S2P) is not regulated directly by changes in cho-
lesterol levels, it can only act after prior Site 1 cleavage has
occurred. Together, this feedback system insures that cells
obtain an uninterrupted supply of optimal levels of choles-
terol and fatty acids, whereas also preventing their accu-
mulation.
SREBP-1 and SREBP-2 activate the same family of
genes, but in different proportions (Smith et al, 1988; Vallett
et al, 1996; Brown and Goldstein, 1998; Narce and Poisson,
2002). In general, SREBP-2 is a more important regulator of
cholesterol synthesis, e.g., cholesterol-depleted cells pref-
erentially upregulate SREBP-2, and SREBP-1 knockout
animals upregulate SREBP-2 and normalize cholesterol
synthesis in response to decreased cellular sterols. SREBP-
1a is as effective as SREBP-2 as a regulator of HMGCoA
synthase and HMGCoA reductase (i.e., cholesterol synthe-
sis), but it has a greater effect on FA synthesis than does
SREBP-2, whereas SREBP-1c primarily regulates FA syn-
thesis. Although both SREBP-1a and SREBP-1c are present
(Harris et al, 1998), SREBP-2 is the predominant species
present in both murine epidermis and in cultured human
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Co-ordinate regulation of epidermal differentiation and lamellar body
secretion by calcium and nuclear hormone receptors.
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keratinocytes. Moreover, SREBP-2 appears to coordinately
regulate cholesterol and fatty acid synthesis in keratin-
ocytes. But its role in the transcriptional regulation of the
lipid synthetic response to barrier disruption is not yet clear.
Ceramide synthesis. SPT catalyzes the initial and first com-
mitted step in ceramide synthesis (Fig 6). Regulation of
ceramide synthesis occurs predominantly by alterations in
the activity of SPT, and/or the availability of palmitic acid, a
substrate for SPT (Holleran et al, 1991a). Thus, alterations in
FA synthesis, potentially regulated by SREBP, could indi-
rectly affect ceramide production (Harris et al, 1998; Narce
and Poisson, 2002). Yet, the expression of this enzyme is
not regulated directly by SREBP, as SPT mRNA levels in-
crease, rather than decrease, with oxysterol blockade of
SREBP activation (Harris et al, 1998). In contrast, SPT ex-
pression increases in response to inflammatory stimuli,
such as UV light, endotoxin, and cytokines (TNF and IL-1)
(Farrell et al, 1998). To what extent and how liposensor ac-
tivators regulate ceramide/glucosylceramides production is a
subject of intense current study (Narce and Poisson, 2002).
Calcium (Ca) signaling of barrier homeostasis. Based
upon phenomena such as the recovery response that fol-
lows acute barrier disruption, and the epidermal response
to altered external humidities, signaling mechanisms must
be operative in the epidermis. The epidermis displays a
distinctive Ca gradient (Menon et al, 1985b), which is reg-
ulated passively by barrier integrity (Elias et al, 2002a), with
the highest levels of Ca in the outer SG, tapering to very low
levels in both the lower epidermis and SC. Indeed, changes
in Ca that occur in response to an altered barrier, rather than
barrier disruption per se, regulate barrier recovery (Lee et al,
1992; Menon et al, 1994b). In the presence of high Ca and
Kþ , barrier recovery is inhibited, but recovery normalizes
with co-applications of inhibitors of voltage-sensitive Ca
channels (e.g., nifedipine, verapamil) (Lee et al, 1992). Ion-
induced regulation of barrier recovery targets LB secretion,
which normally occurs at low rates, sufficient to meet basal
barrier requirements (Menon et al, 1994a). LB secretion
rates accelerate when Ca levels surrounding SG cells de-
cline in parallel with barrier disruption (Menon et al, 1994b)
(Fig 5). Conversely, the high levels of Ca levels in the outer
nucleated layers of the epidermis directly regulate epider-
mal differentiation, after with downregulation of protein syn-
thesis, after acute barrier disruption (Elias et al, 2002b),
followed by increased expression of the same proteins at
later time points as the Ca gradient returns (Ekanayake-
Mudiyanselage et al, 1998). Thus, Ca coordinately regulates
a critical subset of homeostatic responses in the epidermis;
i.e., those related to LB secretion and epidermal differen-
tiation.
Cytokines and growth factors. Both release of cytokines
from a preformed pool (Wood et al, 1996) and production of
several cytokines and growth factors increase with either
acute or prolonged barrier disruption (Wood et al, 1992,
1994b, 1997; Nickoloff and Naidu, 1994), and in chronic
inflammatory skin diseases, which generally display high
levels of primary cytokines, chemokines and other inflam-
matory markers (Kupper, 1990). Although the role of injury-
provoked cytokine generation in epidermal pathophysiology
seems increasingly evident, the importance of individual
cytokines as regulators of metabolic processes that lead to
barrier recovery can be controversial, because occlusion,
which normalizes barrier function artificially, fails to block
the upregulation of cytokine production (Wood et al, 1994a).
Likewise, occlusion has little or no effect on the expression
levels of the receptors for these cytokines (Wood et al,
1994b). Yet, occlusion does, in fact, downregulate expres-
sion levels of primary cytokines in chronically perturbed skin
(e.g., EFA deficiency) (Wood et al, 1994a), and it also blocks
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Metabolic pathways leading to synthesis of cholesterol, fatty acids, and ceramides.
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upregulation of certain growth factors, e.g., amphiregulin
and nerve growth factor, whose expression increases great-
ly after acute barrier disruption (Liou et al, 1997). Finally,
transgenic mice with double knockouts of both the func-
tional IL-1 and TNF receptors display a delay in barrier re-
covery (Kreder et al, 1999); and finally, injections of these
cytokines accelerate barrier recovery (Jensen et al, 1999; Ye
et al, 2002). Primary cytokines could regulate barrier home-
ostasis by two mechanisms: (1) cytokines stimulate kera-
tinocytes lipid synthesis (Ye et al, 2002); and (2) they
stimulate keratinocyte proliferation (Kupper, 1990; Feliciani
et al, 1996).
Repeated disruption of the permeability barrier by either
tape stripping or acetone treatment leads to cutaneous in-
flammation, epidermal hyperplasia, and impaired differen-
tiation (Denda et al, 1996). Because such disturbances in
barrier function can provoke important cutaneous abnor-
malities, it is possible that alterations in barrier function
contribute to the pathogenesis of inflammatory dermatoses,
particularly in disorders, such as psoriasis and AD, which
are associated with barrier abnormalities (Elias and Fein-
gold, 2001). Although specific T cell abnormalities are un-
deniably important in the etiology of psoriasis, AD (Kupper,
1990), and allergic contact dermatitis, the studies described
above support a possible epidermal pathogenesis for these
disorders. Together, these studies show that the SC is an
exquisite biosensor, which responds to barrier disruption
and/or injury with the release and activation of a variety of
signaling molecules, which are putative regulators of the
homeostatic repair response in the underlying epidermis.
These cytokines can, however, also signal a downstream
cascade that eventually leads to inflammation.
Regulation of Desquamation
SC integrity/cohesion. If not the most important defensive
function, perhaps the most distinctive characteristic of the
SC is its ability to desquamate invisibly from the skin sur-
face. Cohesion between adjacent corneocytes is facilitated
by the ‘‘tongue-and-groove’’ arrangement of adjacent cells
(Christophers and Kligman, 1964; Menton and Eisen, 1971),
by CD (¼ specialized desmosomes of the SC), which rivet
together adjacent cells (Serre et al, 1991; Harding et al,
2000), and by extracellular lipids (Chapman et al, 1991). SC
‘‘integrity’’ is a measure of resistance of adjacent corn-
eocytes, to dissociation quantified as a rate of increase in
transepidermal water loss with succesive tape strippings
(Ghadially et al, 1995; Horikoshi et al, 1999; Fluhr et al,
2001). A related index, SC ‘‘cohesion’’, is the amount of
protein removed per stripping (Fluhr et al, 2001). Although
desquamation allows the distal, invisible shedding of corn-
eocytes, dyshesion is largely completed within the lower SC
by proteolytic degradation of CD (Simon et al, 2001). Mor-
phological evidence for loss of CD (Chapman et al, 1991;
Menon and Elias, 1997) is paralleled by the progressive
disappearance of its constituent proteins, desmocollin 1
(DSC1), DSG1, and CDSN) (Lundstrom et al, 1994; Suzuki
et al, 1996; Harding et al, 2000). DSG and DSC are
desmosomal cadherins, encoded by separate genes that
mediate cell-to-cell adhesion. Whereas epidermal desmo-
somes contain four isoforms of DSG and DSC, CD contain
only the DSG1 and DSC1 isoforms (Harding et al, 2000).
CDSN is a recently described, 36–48 kDa differentiation
product of the epidermis, which is secreted by LB (Serre
et al, 1991), accounting for its localization on the extra-
cellular surfaces of CD (Simon et al, 1997), where it shields
DSG1 and DSC1 from premature proteolysis (Serre et al,
1991; Lundstrom et al, 1994), and mediates homophilic
binding to counterparts on adjacent corneocytes (Jonca
et al, 2002). The cross-linking of additional CD constituents
(e.g., envoplakin, periplakin) into the CE further stabilizes
these structures, and in addition, dictates that CD degra-
dation must occur in situ (Harding et al, 2000).
Proteolytic processes leading to desquamation. The
progressive changes that occur in CD and their constituent
peptides point to a critical role for extracellular proteases
in the orchestration of corneocyte shedding (Suzuki et al,
1996; Horikoshi et al, 1999; Harding et al, 2000). At least ten
types of SP activity have been identified in SC, with a
convincing link to desquamation for two SP, SCCE, and
SCTE (kallikrein 7 and 5, respectively) (Hansson et al, 1994;
Ekholm et al, 2000). SCCE is predominantly extracellular
(Sondell et al, 1994), and SCTE activity also is present
in membrane domains (Hachem et al, 2003), but
its subcellular distribution is not known. Based upon
in vitro inhibitor studies, both SCCE and SCTE appear to
be major regulators of desquamation (Suzuki et al, 1993;
Horikoshi et al, 1999; Ekholm et al, 2000). The mRNA for
human SCCE is expressed in the outer epidermis (Sondell
et al, 1994), where it is synthesized as a 25 kDa inactive
precursor, bearing seven amino acid propeptide residue,
delivered to the SC interstices by LB secretion (Hansson
et al, 1994). SCCE can be cleaved to its active form by
SCTE, a 28–33 kDa epidermis-specific, plurifunctional SP
(Brattsand et al, 2000). SCTE not only activates SCCE but it
also degrades CD directly and activates itself (from a
37 kDa precursor) (Ekholm et al, 2000). SCCE activation is
strictly controlled under basal conditions by both the re-
quirement for precursor activation by SCTE (Hansson et al,
1994), and the presence of endogenous SP inhibitors plus
certain inhibitory SC lipids (e.g., cholesterol sulfate and FFA
are inhibitors of SP) (Suzuki et al, 1996; Elias et al, 2004),
and the physiologic state of SC under basal condition (i.e.,
low pH, low Ca2þ , and low hydration; Watkinson et al,
2001; Bouwstra et al, 2003). Conversely, barrier disruption
not only removes inhibitory lipids but it also allows in-
creased Ca2þ and water movement into the SC interstices
(Lee et al, 1992; Menon et al, 1994a), along with an increase
in SC pH, conditions that favor SCCE-mediated desqua-
mation. Although both cysteine and aspartate protease ac-
tivities, with acidic pH optima, have been found in the SC
(Suzuki et al, 1993, 1996; Horikoshi et al, 1998; Watkin-
son et al, 2001; Bernard et al, 2003), assignment of
specific roles for these proteases in desquamation is com-
plicated both by uncertainties about their localization, and
by over-reliance on in vitro models to characterize their pu-
tative activities.
Protease inhibitors in the SC (Table III) Proteolytic events
leading to desquamation are restricted by co-secreted and
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co-localized protease inhibitors in the SC. The SP inhibitors
(SPI) include: secretory leukocyte protease inhibitor (SLPI),
a non-glycosylated, cysteine-enriched, 12 kDa protein,
which potently inhibits SP (Thompson and Ohlsson, 1986;
Wiedow et al, 1990, 1993). SLPI consists of two cysteine
core domains in a tandemly repeating motif, of which one
domain is a trappin gene product (Thompson and Ohlsson,
1986). Trappins comprise a family of low-molecular-weight
proteinase inhibitors, which include another SPI found in
SC, skin-derived antileukocyte proteinase (SKALP) or elafin
(Molhuizen et al, 1993; Alkemade et al, 1994). SKALP is a
smaller, 6 kDa peptide that shares a single linear epitope
of six amino acids with SLPI (Molhuizen et al, 1993).
Because both SLPI and SKALP contain TGase substrate
domains, they are extensively cross-linked to loricrin
residues in the CE (Thompson and Ohlsson, 1986; Molhui-
zen et al, 1993; Alkemade et al, 1994). Likewise, plasmino-
gen activator inhibitor type 2 (PAI-2) represents an
additional SPI that is cross-linked into the CE (Risse et al,
1998, 2000).
The inhibitory spectra of SLPI and SKALP are both
overlapping and complementary. Because SLPI exhibits
stronger inhibitory activity against SCCE than does SKALP,
it is thought to be the principal regulator of SCCE in vivo, but
SKALP is 100-fold more effective as a trypsin inhibitor
than is SLPI (Molhuizen et al, 1993; Alkemade et al, 1994).
Although expressed minimally in normal epidermis, both
SLPI and SKALP expression become highly expressed in
suprabasal cells in psoriasis, during wound healing, and
following epidermal injury (Wiedow et al, 1990; Alkemade
et al, 1994).
The SC has recently been shown to contain another im-
portant SPI, i.e., LEKTI 1 (Komatsu et al, 2002). The genetic
abnormality in Netherton’s syndrome (NS) comprises mu-
tations in the SPINK 5 gene, which encodes the 15-member
LEKTI 1 class of SPI (Chavanas et al, 2000; Bitoun et al,
2002). LEKTI generally are expressed in squamous epithelia
and thymus (Komatsu et al, 2002), but neither their natural
substrates nor their localization in epidermis are known. NS
is a severe autosomal recessive disorder, characterized by
congenital ichthyosis, severe atopic manifestations, and a
propensity for hypernatremic dehydration because of the
severity of the putative barrier defect (Moskowitz et al,
2004). Whereas inflammation and secondary infections are
common features of NS (Traupe, 1989), much more prom-
inent features are the loss (thinning) of SC and the extraor-
dinary barrier abnormality (Moskowitz et al, 2004), which
could result from reduced SC integrity because of un-
checked proteolysis (Komatsu et al, 2002). The presumed
basis for the barrier defect is severe abnormalities in lamel-
lar membrane structure (Fartasch et al, 1999), which could
result from the premature destruction of the lipid-process-
ing enzymes needed to generate the lamellar bilayers from
secreted precursors (Fartasch et al, 1999). Finally, the SC
contains two cysteine protease inhibitors, cystatin a and
cystatin M/E, which again are constituents of the CE (Taka-
hashi et al, 1996; Zeeuwen et al, 2001). Their potential
physiologic role is shown by the Harlequin mouse, where
mutations in cystatin M/E result in ichthyosis and hair ab-
normalities (Zeeuwen et al, 2003).
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